{"pmid":32445484,"title":"A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.","text":["A Real-World Evidence Framework for Optimising Dosing in All Patients with COVID-19.","The SARS-CoV-2 pandemic and associated COVID-19 disease are straining healthcare systems around the world with large numbers of patients becoming ill in a very short period of time, overwhelming healthcare systems in many countries. Several drugs are being repurposed into clinical trials in COVID-19 patients, ranging from drugs already well established in other diseases, such as chloroquine/hydroxychloroquine, lopinavir+ ritonavir, azithromycin and tocilizumab/sarilumab, to those such as remdesivir still in development for their initial indication (1). The opportunities for clinical pharmacology to contribute to the development of new treatments have already been described by others in Clinical Pharmacology & Therapeutics (2).","Clin Pharmacol Ther","Peck, Richard W","Weiner, Daniel","Cook, Jack","Powell, J Robert","32445484"],"abstract":["The SARS-CoV-2 pandemic and associated COVID-19 disease are straining healthcare systems around the world with large numbers of patients becoming ill in a very short period of time, overwhelming healthcare systems in many countries. Several drugs are being repurposed into clinical trials in COVID-19 patients, ranging from drugs already well established in other diseases, such as chloroquine/hydroxychloroquine, lopinavir+ ritonavir, azithromycin and tocilizumab/sarilumab, to those such as remdesivir still in development for their initial indication (1). The opportunities for clinical pharmacology to contribute to the development of new treatments have already been described by others in Clinical Pharmacology & Therapeutics (2)."],"journal":"Clin Pharmacol Ther","authors":["Peck, Richard W","Weiner, Daniel","Cook, Jack","Powell, J Robert"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445484","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1002/cpt.1922","e_drugs":["lopinavir-ritonavir drug combination","tocilizumab","sarilumab","remdesivir","Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1667600475803877378,"score":9.490897,"similar":[{"pmid":32395418,"pmcid":"PMC7211915","title":"An Update on Current Therapeutic Drugs Treating COVID-19.","text":["An Update on Current Therapeutic Drugs Treating COVID-19.","The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2.","Curr Pharmacol Rep","Wu, Renyi","Wang, Lujing","Kuo, Hsiao-Chen Dina","Shannar, Ahmad","Peter, Rebecca","Chou, Pochung Jordan","Li, Shanyi","Hudlikar, Rasika","Liu, Xia","Liu, Zhigang","Poiani, George J","Amorosa, Louis","Brunetti, Luigi","Kong, Ah-Ng","32395418"],"abstract":["The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world. Currently, there are no proven effective vaccines or therapeutic agents against the virus. Current clinical management includes infection prevention and control measures and supportive care including supplemental oxygen and mechanical ventilatory support. Evolving research and clinical data regarding the virologic SARS-CoV-2 suggest a potential list of repurposed drugs with appropriate pharmacological effects and therapeutic efficacies in treating COVID-19 patients. In this review, we will update and summarize the most common and plausible drugs for the treatment of COVID-19 patients. These drugs and therapeutic agents include antiviral agents (remdesivir, hydroxychloroquine, chloroquine, lopinavir, umifenovir, favipiravir, and oseltamivir), and supporting agents (Ascorbic acid, Azithromycin, Corticosteroids, Nitric oxide, IL-6 antagonists), among others. We hope that this review will provide useful and most updated therapeutic drugs to prevent, control, and treat COVID-19 patients until the approval of vaccines and specific drugs targeting SARS-CoV-2."],"journal":"Curr Pharmacol Rep","authors":["Wu, Renyi","Wang, Lujing","Kuo, Hsiao-Chen Dina","Shannar, Ahmad","Peter, Rebecca","Chou, Pochung Jordan","Li, Shanyi","Hudlikar, Rasika","Liu, Xia","Liu, Zhigang","Poiani, George J","Amorosa, Louis","Brunetti, Luigi","Kong, Ah-Ng"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32395418","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s40495-020-00216-7","keywords":["anakinra","azithromycin","covid-19","chloroquine","convalescent plasma","epoprostenol","favipiravir","hydroxychloroquine","lopinavir","methylprednisolone","nitric oxide","oseltamivir","remdesivir","sar-cov-2","sarilumab","sirolimus","tocilizumab","traditional chinese medicine","umifenovir","vitamin c"],"locations":["Azithromycin"],"topics":["Treatment"],"weight":1,"_version_":1666627827806502913,"score":135.32155},{"pmid":32243270,"pmcid":"PMC7176266","title":"Potential therapeutic agents against COVID-19: What we know so far.","text":["Potential therapeutic agents against COVID-19: What we know so far.","The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.","J Chin Med Assoc","Lu, Chih-Chia","Chen, Mei-Yu","Chang, Yuh-Lih","32243270"],"abstract":["The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19."],"journal":"J Chin Med Assoc","authors":["Lu, Chih-Chia","Chen, Mei-Yu","Chang, Yuh-Lih"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32243270","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1097/JCMA.0000000000000318","e_drugs":["remdesivir","Hydroxychloroquine","Ribavirin","lopinavir-ritonavir drug combination","Chloroquine","tocilizumab","favipiravir","sarilumab"],"topics":["Treatment"],"weight":1,"_version_":1666138492081537024,"score":131.31853},{"pmid":32425199,"pmcid":"PMC7228893","title":"Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.","text":["Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.","Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes.","Am J Cardiol","Aggarwal, Gaurav","Henry, Brandon Michael","Aggarwal, Saurabh","Bangalore, Sripal","32425199"],"abstract":["Coronavirus disease 2019 (COVID-19) has become a global pandemic. It is still uncontrolled in most countries and no therapies are currently available. Various drugs are under investigation for its treatment. The disease is known to have worse outcomes in patients who have underlying cardiovascular disease. Chloroquine/hydroxychloroquine, azithromycin, remdesivir and lopinavir/ritonavir are currently being studied in trials and show some promise. Conduction disorders, heart failure and mortality have been reported with the use of these drugs. It is important to have a knowledge of potential cardiotoxic effects of these drugs before using them for COVID-19 patients for better allocation of healthcare resources and improvement in clinical outcomes."],"journal":"Am J Cardiol","authors":["Aggarwal, Gaurav","Henry, Brandon Michael","Aggarwal, Saurabh","Bangalore, Sripal"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32425199","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.amjcard.2020.04.054","keywords":["covid-19","cardiovascular","coronavirus"],"e_drugs":["remdesivir","Azithromycin","lopinavir-ritonavir drug combination"],"topics":["Treatment"],"weight":1,"_version_":1667352728822611970,"score":130.44252},{"pmid":32329520,"title":"Current pharmacological treatments for COVID-19: what's next?","text":["Current pharmacological treatments for COVID-19: what's next?","Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications.","Br J Pharmacol","Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa","32329520"],"abstract":["Starting from December 2019 the novel SARS-Cov-2 has spread all over the world, being recognized as the causing agent of COVID-19. Since nowadays no specific drug therapies neither vaccines are available for the treatment of COVID-19, drug repositioning may offer a strategy to efficiently control the clinical course of the disease and the spread of the outbreak. In this paper we aim to describe the main pharmacological properties, including data on mechanism of action, safety concerns and drug-drug interactions, of drugs currently administered in patients with COVID-19, focusing on antivirals and drugs with immune-modulatory and/or anti-inflammatory properties. Where available, data from clinical trials involving patients with COVID-19 were reported. Several studies have been registered worldwide and a number of drugs were repurposed to face the new health emergency of COVID-19. For many of these drugs, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab, preliminary clinical trials seem to support their benefit in improving patients' clinical conditions. However, adequate clinical trials are necessary to reach any firm conclusion on the efficacy and safety profiles of these compounds. Even though drug repurposing is necessary, it requires caution. Too many drugs that are currently tested in patients with COVID-19 have peculiar safety profiles. In conclusion, while waiting for the development of effective preventive measures, such as vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. It is conceivable that very soon their results will help us in defining the best way to treat COVID-19 and reducing its symptoms and complications."],"journal":"Br J Pharmacol","authors":["Scavone, Cristina","Brusco, Simona","Bertini, Michele","Sportiello, Liberata","Rafaniello, Concetta","Zoccoli, Alice","Berrino, Liberato","Racagni, Giorgio","Rossi, Francesco","Capuano, Annalisa"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329520","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1111/bph.15072","keywords":["covid-19","anti-inflammatory agents","antivirals","clinical practice","clinical research","immuno-modulatory agents","literature review","pharmacological treatments"],"e_drugs":["remdesivir","tocilizumab","lopinavir-ritonavir drug combination","favipiravir"],"topics":["Treatment"],"weight":1,"_version_":1666138494591827971,"score":128.32259},{"pmid":32436445,"title":"Potential specific therapies in COVID-19.","text":["Potential specific therapies in COVID-19.","COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section.","Ther Adv Respir Dis","Gul, Muhammad Hamdan","Htun, Zin Mar","Shaukat, Nauman","Imran, Muhammad","Khan, Ahmad","32436445"],"abstract":["COVID-19 has grown into a global pandemic that has strained healthcare throughout the world. There is a sense of urgency in finding a cure for this deadly virus. In this study, we reviewed the empiric options used in common practice for COVID-19, based on the literature available online, with an emphasis on human experiences with these treatments on severe acute respiratory syndrome-associated coronavirus (SARS-COV-1) and other viruses. Convalescent blood products are the most promising potential treatment for use in COVID-19. The use of chloroquine or hydroxychloroquine (HCQ), remdesivir, and tocilizumab are some of the other promising potential therapies; however, they are yet to be tested in randomized clinical trials (RCTs). The use of lopinavir-ritonavir did not prove beneficial in a large RCT. The use of corticosteroids should be avoided in COVID-19 pneumonia unless used for other indications, based on the suggestion of harm in patients with SARS-COV-1 and Middle Eastern Respiratory Syndrome (MERS) infection. The reviews of this paper are available via the supplemental material section."],"journal":"Ther Adv Respir Dis","authors":["Gul, Muhammad Hamdan","Htun, Zin Mar","Shaukat, Nauman","Imran, Muhammad","Khan, Ahmad"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436445","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1177/1753466620926853","keywords":["il-6","mers","sars-cov-1","convalescent blood products","coronavirus","corticosteroids convalescent sera","favipiravir","interferons","lopinavir-ritonavir","novel virus","remdesivir","ribavirin","tocilizumab"],"e_drugs":["tocilizumab","Chloroquine","lopinavir-ritonavir drug combination","Hydroxychloroquine","remdesivir"],"topics":["Treatment"],"weight":1,"_version_":1667521393594466304,"score":119.38966}]}